The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study)

The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study)

Abstract Background Tumor necrosis factor α inhibitors (TNFi) is effective for rheumatoid arthritis (RA) patients who fail to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Because of high cost, the discontinuation is common but often lead to disease relapse. The study aim...

Full description

Bibliographic Details
Main Authors: Juan Zhao, Wei Zhou, Yangfeng Wu, Ping Ji, Li Yang, Xiaoyan Yan, Zhuoli Zhang
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Medical Informatics and Decision Making
Subjects:
Rheumatoid arthritis
Pharmaceutical economics analysis
Cost-effectiveness analysis
Cost-utility analysis
Relapse
Online Access:https://doi.org/10.1186/s12911-021-01449-2

Internet

https://doi.org/10.1186/s12911-021-01449-2

Similar Items